Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
KCNE1 tunes the sensitivity of KV7.1 to polyunsaturated fatty acids by moving turret residues close to the binding site.
Larsson JE
,
Larsson HP
,
Liin SI
.
???displayArticle.abstract???
The voltage-gated potassium channel KV7.1 and the auxiliary subunit KCNE1 together form the cardiac IKs channel, which is a proposed target for future anti-arrhythmic drugs. We previously showed that polyunsaturated fatty acids (PUFAs) activate KV7.1 via an electrostatic mechanism. The activating effect was abolished when KV7.1 was co-expressed with KCNE1, as KCNE1 renders PUFAs ineffective by promoting PUFA protonation. PUFA protonation reduces the potential of PUFAs as anti-arrhythmic compounds. It is unknown how KCNE1 promotes PUFA protonation. Here, we found that neutralization of negatively charged residues in the S5-P-helix loop of KV7.1 restored PUFA effects on KV7.1 co-expressed with KCNE1 in Xenopus oocytes. We propose that KCNE1 moves the S5-P-helix loop of KV7.1 towards the PUFA-binding site, which indirectly causes PUFA protonation, thereby reducing the effect of PUFAs on KV7.1. This mechanistic understanding of how KCNE1 alters KV7.1 pharmacology is essential for development of drugs targeting the IKs channel.
Figure 1. Concept of DHA-induced shift in KV7.1 channel voltage dependence.(A) Schematic side view of one subunit of KCNE1 and KV7.1. KCNE1 is in light orange. KV7.1 is in grey (transmembrane helices S1-S4 forming the voltage-sensing domain) and blue (transmembrane helices S5 and S6 forming the pore domain). P denotes pore helix. (B) Schematic top-down view of the KV7.1+E1 channel complex. Same coloring as in A. The putative localization of a polyunsaturated fatty acid between neighboring voltage-sensing domains is included. (C) Cartoon and representative example of previously published key data showing that at pH 7.4 70 µM DHA facilitates KV7.1 channel opening by electrostatically facilitating outward S4 movement, seen as a shift of G(V) curve towards more negative voltages (modified data from Liin et al. [2015b]). (D) Cartoon and representative example of previously published key data showing that at pH 7.4, co-expression with KCNE1 decreases the local pH at the PUFA-binding site, which renders DHA uncharged and ineffective. As a consequence, 70 µM DHA fails to facilitate KV7.1+E1 channel opening at pH 7.4, seen as a lack of shift of G(V) curve toward more negative voltages (modified data from Liin et al. [2015b]). (E) KCNE1 changes the pH dependence of the DHA-induced shift in the voltage dependence of channel opening, ÎV50. [DHA]=70 µM. The ÎV50 values were normalized to the fitted maximum ÎV50 (using Equation 2) at very basic pH for each channel type to better visualize the different pKa values for the different channel constructs. Relative ÎV50 are expressed as mean ± SEM (modified and complemented data from Liin et al. [2015b]). Best fit of Equation (2): pKa = pH 8.7 for KV7.1+E1 and 7.8 for KV7.1 alone. n = 3â6 per data point.
Figure 2. Removal of KCNE1 extracellular residues did not restore KV7.1-like DHA effect.(A) Sequences of the N-terminal segments of WT human KCNE1 and three different KCNE1 mutants. Acidic residues colored red and basic residues colored blue. (B) pH dependence of the DHA effect (70 µM) on the relative ÎV50 for each KCNE1 mutant co-expressed with WT KV7.1. Data shown as mean ± SEM. n = 3â6 per data point. Fits for KV7.1 alone (black dashed line) and KV7.1+E1 (solid black line) from data in Figure 1E are shown for comparison. (C) Apparent pKa for the DHA effect on indicated mutants. Data shown as mean ± asymmetrical 95% confidence interval determined using Equation 2 on the data in B (best fit with Equation 2: pKa = pH 8.7 for KV7.1+E1/âN2-38, 8.8 for KV7.1+E1/D39C/E43C, and 8.5 for KV7.1+E1/K41C).
Figure 3. Removal of negative charges in the S5-P-helix loop partially or completely restored KV7.1-like DHA effect.(A) Sequences of the S5-P-helix loop of WT human KV7.1 and five KV7.1 mutants. Acidic residues colored red. (B) pH dependence of the DHA effect (70 µM) on the relative ÎV50 for each KV7.1 mutants co-expressed with WT KCNE1. Data shown as mean ± SEM. n = 3â7 for each data point. Fits for KV7.1 alone (black dashed line) and KV7.1+E1 (solid black line) from data in Figure 1E are shown for comparison. (C) Apparent pKa for the DHA effect on indicated mutants. Data shown as mean ± asymmetrical 95% confidence interval determined using Equation 2 (best fit with Equation 2: pKa = pH 8.3 for KV7.1/E284C + E1, 8.2 for KV7.1/D286C + E1, 7.8 for KV7.1/E290C + E1, 8.1 for KV7.1/E295C + E1, and 8.4 for KV7.1/D301C + E1). Figure 3âfigure supplement 1 is associated with Figure 3.Figure 3âfigure supplement 1. Alternative substitutions at position 290 support the hypothesis that the negative charge at position 290 is important for DHA protonation in the presence of KCNE1.(A) pH dependence of the DHA effect (70 µM) on the relative ÎV50 for KV7.1/E290A + E1 and KV7.1/E290C + E1 in the presence of DTT (0.5 mM DTT was added to the incubation solution and control solution to prevent disulphide bond formation during oocyte incubation and experiment). Data shown as mean ± SEM. n = 4â7 for each data point. Fit for KV7.1+E1 (solid black line) and KV7.1 alone (black dashed line) are shown for comparison. Best fit with Equation 2: pKa = pH 8.0 for KV7.1/E290A + E1, and 7.9 for KV7.1/E290C + E1 in DTT. (B) pH dependence of the DHA effect (70 µM) on the relative ÎV50 for KV7.1/E290A + E1 and KV7.1/E290R + E1. Data shown as mean ± SEM. n = 3â7 for each data point. Fit for KV7.1+E1 (solid black line) is shown for comparison. Best fit with Equation 2: pKa = pH 8.0 for KV7.1/E290A + E1, and 7.7 for KV7.1/E290R + E1.
Figure 4. The charge at E290 is important for the PUFA effect.(A) pH dependence of the DHA effect (70 µM) on the relative ÎV50 for KV7.1/E290C expressed without KCNE1. Data shown as mean ± SEM. n = 4â14 for each data point. Fits for KV7.1 alone (black dashed line), KV7.1+E1 (solid black line), and KV7.1/E290C co-expressed with KCNE1 (red solid line) are shown for comparison. (B) Apparent pKa for the DHA effect on indicated mutants. Data shown as mean ± asymmetrical 95% confidence interval determined using Equation 2 (best fit with Equation 2: pKa = pH 8.0 for KV7.1/E290C). (C) Summary of âV50 induced by 70 µM DHA at pH 8.2 for indicated mutants. The E290C mutation only increases the DHA effect when KCNE1 is co-expressed. Data shown as mean ± SEM. n = 3â5. One-way ANOVA with Tukeyâs multiple comparison test. *** denotes p<0.001 and ns denotes p>0.05. (D) Summary of âV50 induced by 70 µM DHA at pH 8.2 for indicated mutants. MTSESâmodification of E290C is denoted by -SESâ. MTSESâmodification of E290C restores WT KV7.1+E1 like response to DHA. Data shown as mean ± SEM. n = 3â7. One-way ANOVA with Dunnettâs multiple comparison test and KV7.1/E290C-SESâ+E1 set as control. *** denotes p<0.001 and ns denotes p>0.05. (EâF) Representative effect of DHA (70 µM) on the G(V) curve at pH 8.2 for (E) KV7.1/E290C + E1 and (F) KV7.1/E290C-SESâ+E1. Control data in black and DHA data in red. (G) Summary of effect of arachidonoyl amine (AA+, 70 µM, structure on top) on V50 of indicated mutants at pH 7.4. The E290C mutation decreases the AA+ effect on KV7.1+E1. Data shown as mean ± SEM (modified WT data from Liin et al. [2015b]). n = 3â10. One-way ANOVA with Dunnettâs multiple comparison test and KV7.1/E290C + E1 set as control. * denotes p<0.05 and ns denotes p>0.05. Schematic illustration describes electrostatic AA+-induced prevention of outward S4 movement (right). Figure 4âfigure supplement 1 is associated with Figure 4.Figure 4âfigure supplement 1. Lack of effect of MTSESâ modification on intrinsic properties of KV7.1/E290C + E1.(A) Representative current family for KV7.1/E290C + E1 before (left) and after (right) MTSESâ (10 mM) modification at pH 7.4. Activating voltage steps from â80 mV to + 60 mV from a holding voltage of â80 mV. Tail voltage to â20 mV. (B) Representative normalized G(V) curve for KV7.1/E290C + E1 before (open symbols) and after (red symbols) MTSESâ (10 mM) modification. The average âV50 induced by MTSESâ modification was â4.0 ± 2.5 mV (n = 3).
Figure 5. Proposed model of how KCNE1 induces protonation of PUFAs.(A) PUFA (black) binds to KV7.1 in the lipid-filled space between two voltage-sensing domains (grey). The negatively charged PUFA head attracts the positively charges in S4 to facilitate channel activation. In KV7.1 alone, the negatively charged S5-P-helix loop (black with red negative charge) belonging to the pore region (blue) is not close to the PUFA-binding site and will therefore not induce PUFA protonation. (B) KCNE1 (light orange) co-expression with KV7.1 induces a conformational change that moves the S5-P-helix loop closer to the PUFA. The negative charges in the S5-P-helix loop, especially E290, attract protons to the PUFA binding site, which decreases the local pH. Decreased local pH causes PUFA protonation, which renders the PUFA uncharged and ineffective. (C) When negative charges in the S5-P-helix loop are neutralized, the ability of the S5-P-helix loop to attract protons is reduced. This tends to preserve the negative charge and the activating effect of the PUFA even in the presence of KCNE1. (D) Localization of indicated residues in the S5-P-helix loop of human KV7.1, side view (left) and top-down view (right) (homology model based on the Cryo EM structure of Xenopus KV7.1 [Sun and MacKinnon, 2017] and KV1.2/2.1 [Long et al., 2007]). Arrows indicate the suggested translocation of the turret region towards the PUFA binding site. Same color coding as in Figure 3 panel B and C (E284 in purple, D286 in pink, E290 in red, E295 in orange, and D301 in blue).
Abitbol,
Stilbenes and fenamates rescue the loss of I(KS) channel function induced by an LQT5 mutation and other IsK mutants.
1999, Pubmed,
Xenbase
Abitbol,
Stilbenes and fenamates rescue the loss of I(KS) channel function induced by an LQT5 mutation and other IsK mutants.
1999,
Pubmed
,
Xenbase
Anderson,
Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.
2014,
Pubmed
Barhanin,
K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current.
1996,
Pubmed
,
Xenbase
Barro-Soria,
KCNE1 and KCNE3 modulate KCNQ1 channels by affecting different gating transitions.
2017,
Pubmed
,
Xenbase
Börjesson,
Lipoelectric modification of ion channel voltage gating by polyunsaturated fatty acids.
2008,
Pubmed
,
Xenbase
Broomand,
Electrostatic domino effect in the Shaker K channel turret.
2007,
Pubmed
,
Xenbase
Busch,
The role of the IsK protein in the specific pharmacological properties of the IKs channel complex.
1997,
Pubmed
,
Xenbase
Busch,
Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes.
1994,
Pubmed
,
Xenbase
Chung,
Location of KCNE1 relative to KCNQ1 in the I(KS) potassium channel by disulfide cross-linking of substituted cysteines.
2009,
Pubmed
Elinder,
Extracellular Linkers Completely Transplant the Voltage Dependence from Kv1.2 Ion Channels to Kv2.1.
2016,
Pubmed
,
Xenbase
Gao,
Desensitization of chemical activation by auxiliary subunits: convergence of molecular determinants critical for augmenting KCNQ1 potassium channels.
2008,
Pubmed
Goldenberg,
Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome.
2006,
Pubmed
Hedley,
The genetic basis of long QT and short QT syndromes: a mutation update.
2009,
Pubmed
Jespersen,
Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes.
2002,
Pubmed
,
Xenbase
Liin,
Polyunsaturated fatty acid analogs act antiarrhythmically on the cardiac IKs channel.
2015,
Pubmed
,
Xenbase
Liin,
The KCNQ1 channel - remarkable flexibility in gating allows for functional versatility.
2015,
Pubmed
Liin,
Fatty acid analogue N-arachidonoyl taurine restores function of IKs channels with diverse long QT mutations.
2016,
Pubmed
,
Xenbase
Long,
Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment.
2007,
Pubmed
Mattmann,
Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.
2012,
Pubmed
Nakajo,
KCNQ1 channel modulation by KCNE proteins via the voltage-sensing domain.
2015,
Pubmed
Nerbonne,
Molecular physiology of cardiac repolarization.
2005,
Pubmed
Perry,
Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.
2016,
Pubmed
,
Xenbase
Priori,
Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.
2004,
Pubmed
Salata,
A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents.
1998,
Pubmed
,
Xenbase
Sanguinetti,
Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.
1996,
Pubmed
,
Xenbase
Schmitt,
The novel C-terminal KCNQ1 mutation M520R alters protein trafficking.
2007,
Pubmed
Seebohm,
Pharmacological activation of normal and arrhythmia-associated mutant KCNQ1 potassium channels.
2003,
Pubmed
,
Xenbase
Sun,
Cryo-EM Structure of a KCNQ1/CaM Complex Reveals Insights into Congenital Long QT Syndrome.
2017,
Pubmed
,
Xenbase
Wang,
Identification of a key residue in Kv7.1 potassium channel essential for sensing external potassium ions.
2015,
Pubmed
Xu,
Probing binding sites and mechanisms of action of an I(Ks) activator by computations and experiments.
2015,
Pubmed
Xu,
Building KCNQ1/KCNE1 channel models and probing their interactions by molecular-dynamics simulations.
2013,
Pubmed
Yu,
Dynamic subunit stoichiometry confers a progressive continuum of pharmacological sensitivity by KCNQ potassium channels.
2013,
Pubmed